Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
All News
Headline News
Press Releases
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
From CatalYm GmbH
Via Business Wire
Omdia: AMOLED 2H25 Display Revenues to Reach $29 Billion, Falling Short of 2H24
From OMDIA
Via Business Wire
Tickers TTGT
Omdia: Music Publishing Revenue Growth to Outshine Recorded-Music Over the Next Five Years
From Informa TechTarget, Inc.
Via Business Wire
Tickers TTGT
StratifAI Joins With MSK iHub Challenge Cohort to Advance Validation of Polaris™ Through Access to World-Class Clinical Datasets
From StratifAI
Via Business Wire
Imagine Communications Acquires Pixel Power From Rohde & Schwarz
From Imagine Communications
Via Business Wire
Leading Global Businesses Unite to Launch Carbon Measures
From Carbon Measures
Via Business Wire
Caranx Medical (CarvOlix group) to Showcase Latest Updates at the 37th Annual Transcatheter Cardiovascular Therapeutics® Conference (TCT)
From Caranx Medical
Via Business Wire
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
From Iksuda Therapeutics
Via Business Wire
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Abyan Capital Launches Shariah-Compliant, Self-Directed Access to US Markets with Alpaca
From Alpaca
Via Business Wire
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
From Genentech
Via Business Wire
Tickers RHHBY
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
Tickers NTRA
AM Best to Host Annual MENA Insurance Market Briefing in Dubai
From AM Best
Via Business Wire
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
Tickers RHHBY
Lone Star Announces Sale of Xella to Holcim
From Lone Star Funds
Via Business Wire
Bass Pro Shops Ranked Highest in 2025 Boat Industry Study Measuring Response to Sales Customer Calls
From Pied Piper Management Company, LLC
Via Business Wire
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products
From Biedermann Motech
Via Business Wire
AM Best to Participate at 2025 Shanghai International Reinsurance Conference
From AM Best
Via Business Wire
AM Best to Host Market Briefing at 2025 Singapore International Reinsurance Conference
From AM Best
Via Business Wire
The Republic of Korea Selects L3Harris for Airborne Early Warning and Control Aircraft Program
From L3Harris Technologies
Via Business Wire
Tickers LHX
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
From Arcus Biosciences
Via Business Wire
Tickers RCUS
F5, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – FFIV
From The DJS Law Group
Via Business Wire
Tickers FFIV
Freshpet, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – FRPT
From The DJS Law Group
Via Business Wire
Tickers FRPT
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
From Incyte
Via Business Wire
Tickers INCY
FFIV Investors Have Opportunity to Join F5, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Tickers FFIV
FRPT Investors Have Opportunity to Join Freshpet, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Tickers FRPT
American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
From Citi
Via Business Wire
Tickers C
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
Tickers SMMT
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
From Daiichi Sankyo
Via Business Wire
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
From Daiichi Sankyo
Via Business Wire
Tickers MRK
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.